<unk>  (former developmental code name TAT-59) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was under development in Japan for the treatment of breast cancer but was abandoned and never marketed. It reached phase III clinical trials for this indication before development was discontinued. The drug is a<unk>  ester and prodrug of<unk>  (DP-TAT-59) with improved water solubility that was better suited for clinical development.<unk>  has been found to be 3- to 10-fold as potent as tamoxifen in inhibiting breast cancer cell growth in in vitro models. It is a derivative of afimoxifene (4-hydroxytamoxifen) in which an additional 4-isopropyl group is present in the β-phenyl ring.
Miproxifene phosphate
Milbemycin oxime
Tuberculinic acid
Rubitecan
Silver sulfadiazine
Nifurtimox
Ioxaglic acid
Fidaxomicin